- Home
- BKYI vs GLMD Comparison
BKYI vs GLMD Comparison
Compare BKYI & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BKYI
- GLMD
- Stock Information
- Founded
- BKYI 1993
- GLMD 2000
- Country
- BKYI United States
- GLMD Israel
- Employees
- BKYI N/A
- GLMD N/A
- Industry
- BKYI Computer Software: Prepackaged Software
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- BKYI Technology
- GLMD Health Care
- Exchange
- BKYI Nasdaq
- GLMD Nasdaq
- Market Cap
- BKYI 2.7M
- GLMD 3.0M
- IPO Year
- BKYI 1997
- GLMD 2014
- Fundamental
- Price
- BKYI $0.83
- GLMD $1.19
- Analyst Decision
- BKYI
- GLMD Hold
- Analyst Count
- BKYI 0
- GLMD 1
- Target Price
- BKYI N/A
- GLMD N/A
- AVG Volume (30 Days)
- BKYI 222.7K
- GLMD 4.8M
- Earning Date
- BKYI 05-15-2025
- GLMD 05-29-2025
- Dividend Yield
- BKYI N/A
- GLMD N/A
- EPS Growth
- BKYI N/A
- GLMD N/A
- EPS
- BKYI N/A
- GLMD N/A
- Revenue
- BKYI $6,929,571.00
- GLMD N/A
- Revenue This Year
- BKYI $7.45
- GLMD N/A
- Revenue Next Year
- BKYI N/A
- GLMD N/A
- P/E Ratio
- BKYI N/A
- GLMD N/A
- Revenue Growth
- BKYI N/A
- GLMD N/A
- 52 Week Low
- BKYI $0.52
- GLMD $1.21
- 52 Week High
- BKYI $3.68
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- BKYI 52.95
- GLMD 38.80
- Support Level
- BKYI $0.74
- GLMD $1.16
- Resistance Level
- BKYI $0.87
- GLMD $1.33
- Average True Range (ATR)
- BKYI 0.08
- GLMD 0.14
- MACD
- BKYI 0.01
- GLMD 0.00
- Stochastic Oscillator
- BKYI 47.08
- GLMD 7.41
About BKYI BIO-key International Inc.
BIO-key International Inc is a fingerprint biometric technology company. It develops and markets fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions. Its product portfolio comprises SideSwipe, SidePass, EcoID, WEB-key, and others. The company generates its revenue in the form of Services, License fees, and others.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.